3.10
+0.07(+2.31%)
Currency In USD
Address
345 Park Avenue South
New York City, NY 10010
United States of America
Phone
646 844 0337
Website
Sector
Healthcare
Industry
Biotechnology
Employees
28
First IPO Date
October 22, 2014
| Name | Title | Pay | Year Born |
| Mr. Jesse Shefferman | Co-founder, Chief Executive Officer, President & Director | 1.14M | 1972 |
| Mr. Patrick Fabbio M.B.A. | Chief Financial Officer | 782,409 | 1968 |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder & Chief Scientific Operations Officer | 962,033 | 1981 |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer | 0 | 1978 |
| Ms. Hannah Fry | Vice President, Principal Accounting Officer & Controller | 0 | 1991 |
| Dr. Shane Williams Ph.D. | Chief People Officer | 0 | N/A |
| Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Ms. Mary J. Grendell J.D. | General Counsel & Corporate Secretary | 0 | N/A |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.